Author

Louise Frenette

Observed name: L. Frenette

Observed institution: Q & T Research

OpenAlex ID: A5041173948

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

2019 · Hertzel C Gerstein, Helen M Colhoun, et al. · The Lancet · 3,264

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

2019 · Hertzel C Gerstein, Helen M Colhoun, et al. · The Lancet · 650

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

2016 · Fernand Labrie, David F. Archer, et al. · Menopause The Journal of The North American Menopause Society · 251

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

2018 · Fernand Labrie, David F. Archer, et al. · Menopause The Journal of The North American Menopause Society · 120

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy

2015 · Fernand Labrie, Leonard Derogatis, et al. · The Journal of Sexual Medicine · 94

Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults

2010 · Joanne M. Langley, Louise Frenette, et al. · The Journal of Infectious Diseases · 91

Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study

2011 · Joanne M. Langley, George Risi, et al. · The Journal of Infectious Diseases · 80

PDF

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years

2016 · Thanyawee Puthanakit, Li-Min Huang, et al. · The Journal of Infectious Diseases · 50

PDF

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults

2016 · Anuradha Madan, Nathan Segall, et al. · The Journal of Infectious Diseases · 46

PDF

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial

2017 · Li-Min Huang, Thanyawee Puthanakit, et al. · The Journal of Infectious Diseases · 27

PDF

AS03B-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial

2014 · Pope Kosalaraksa, Robert Jeanfreau, et al. · The Journal of Infectious Diseases · 24

A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine

2012 · Joanne M Langley, Louise Frenette, et al. · BMC Infectious Diseases · 17

PDF

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months

2011 · George Risi, Louise Frenette, et al. · Vaccine · 17

Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial

2014 · Joanne M. Langley, Louise Frenette, et al. · Vaccine · 16

PDF

Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial

2017 · Anuradha Madan, Harry Collins, et al. · Vaccine · 15

PDF

Corrigendum to “Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months” [Vaccine 29 (2011) 6408–6418]

2012 · George Risi, Louise Frenette, et al. · Vaccine · 3

Reactogenicity and safety of AS03 B -adjuvanted H5N1 influenza vaccine in children: an open-label, one-way, crossover trial

2017 · Patricia Izurieta, Pope Kosalaraksa, et al. · Asian Biomedicine

PDF

Safety and Cross-Reactive Immunogenicity of Two H5N1 A/Indonesia/5/2005 (Clade 2.1) AS-Adjuvanted Prepandemic Candidate Influenza Vaccines: A Phase I/II Clinical Trial

2008 · J. Langley, L. Frenette, et al. · International Journal of Infectious Diseases

PDF

Works count: 18

Citation count: 4,765

H-index: 15

I10-index: 15